We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.35%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.65B
AUM Growth
+$205M
Cap. Flow
-$69.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$17.1M
2
PFE icon
Pfizer
PFE
+$15.6M
3
BIIB icon
Biogen
BIIB
+$14.1M
4
MCK icon
McKesson
MCK
+$12.2M
5
AVTR icon
Avantor
AVTR
+$9.51M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$24.9M
3
HUM icon
Humana
HUM
+$18.5M
4
AZN icon
AstraZeneca
AZN
+$15.7M
5
MOH icon
Molina Healthcare
MOH
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Real Estate 1.68%
3 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
76
Intellia Therapeutics
NTLA
$1.49B
$5.38M 0.2%
154,269
– –
XNCR icon
77
Xencor
XNCR
$1.5B
$5.22M 0.2%
200,328
– –
SNN icon
78
Smith & Nephew
SNN
$13.3B
$4.89M 0.18%
181,710
– –
ONC
79
BeOne Medicines Ltd
ONC
$32.8B
$4.61M 0.17%
20,952
– –
MPT
80
Medical Properties Trust
MPT
$2.77B
$4.59M 0.17%
411,743
– –
ADUS icon
81
Addus HomeCare
ADUS
$2.16B
$4.22M 0.16%
42,380
-41,252
-49% -$4.31M
RXDX
82
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$4.21M 0.16%
38,237
+6,732
+21% +$437K
TEVA icon
83
Teva Pharmaceuticals
TEVA
$40.8B
$4.19M 0.16%
459,651
– –
ARWR icon
84
Arrowhead Research
ARWR
$11.9B
$4.07M 0.15%
100,422
-56,453
-36% -$1.87M
DOC icon
85
Healthpeak Properties
DOC
$15.1B
$3.77M 0.14%
150,392
– –
CRBU icon
86
Caribou Biosciences
CRBU
$145M
$3.56M 0.13%
567,147
– –
KURA icon
87
Kura Oncology
KURA
$800M
$3.52M 0.13%
+283,281
New +$4.12M
CYTK icon
88
Cytokinetics
CYTK
$10.5B
$3.44M 0.13%
75,139
– –
APLS
89
DELISTED
Apellis Pharmaceuticals
APLS
$3.43M 0.13%
66,426
-199,650
-75% -$10.6M
COR icon
90
Cencora
COR
$60.6B
$3.38M 0.13%
+20,417
New +$3.23M
HR icon
91
Healthcare Realty
HR
$7.28B
$3.37M 0.13%
174,686
– –
IONS icon
92
Ionis Pharmaceuticals
IONS
$8.6B
$3.32M 0.13%
87,840
– –
XENE icon
93
Xenon Pharmaceuticals
XENE
$6.06B
$3.3M 0.12%
83,714
+21,981
+36% +$800K
ADPT icon
94
Adaptive Biotechnologies
ADPT
$3.59B
$3.23M 0.12%
422,281
– –
IBB icon
95
iShares Biotechnology ETF
IBB
$9.18B
$3.23M 0.12%
24,569
– –
MLTX icon
96
MoonLake Immunotherapeutics
MLTX
$1.57B
$3.15M 0.12%
300,000
– –
RARE icon
97
Ultragenyx Pharmaceutical
RARE
$2.45B
$3.11M 0.12%
67,065
– –
STE icon
98
Steris
STE
$22.3B
$3.08M 0.12%
16,669
– –
VTR icon
99
Ventas
VTR
$48B
$3M 0.11%
66,681
– –
SNDX icon
100
Syndax Pharmaceuticals
SNDX
$1.69B
$3M 0.11%
+117,717
New +$2.75M
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Tekla Capital Management held 181 positions worth $2.65B, up 8.4% from $2.44B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2022 filing shows 13 new, 25 increased, 35 reduced and 9 closed positions. Its largest new stake was Avantor: 459,488 shares worth $9.69M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2022 buy was Avantor: 459,488 shares worth $9.69M.
  • Tekla Capital Management added most to Eli Lilly in Q4 2022, an estimated $17.1M increase.
  • Tekla Capital Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $26.5M.
  • Tekla Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $10.6M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.65B portfolio in Q4 2022.
  • Tekla Capital Management opened 13 new positions and closed 9 in Q4 2022.
  • Tekla Capital Management's portfolio value rose 8.4% quarter-over-quarter to $2.65B.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.